Federally-Listed PSOs

Below is a list of PSOs that are currently listed by AHRQ. A health care provider can only obtain the confidentiality and privilege protections of the Patient Safety Act by working with a Federally-listed PSO.

Use the categories on the left to filter the list of PSOs or search a PSO name.

Note: AHRQ updates the PSO information contained within the directories weekly, as needed; changes are made when there are newly listed PSOs and/or when existing information requires revision. Changes that would otherwise be effective on a weekend day or holiday will be effective on the next business day. Information contained in the directories is based on attestations that the PSOs provide. To update PSO contact information, please use the Change of Listing Information form; to update profile information, please go to the PSO PPC Web site.

There are 86 total PSOs listed by AHRQ.

DARTNet Institute Patient Safety Organization - P0176
Component of Parent Org(s):
  • DARTNet Institute
Effective Date and Time of Initial Listing: December 22, 2015 12:01 AM ET
Mailing address: 12635 East Montview Blvd, Mailbox 5, Aurora, CO 80045
PSO Phone Number: 800-434-0278
Point of Contact: Danica Schrader
Point of Contact Phone: (720) 232-6153
Point of Contact Email: Danica.Schrader@dartnet.info (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 12/22/2019 through 12/21/2021
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No
Louisiana Alliance for Patient Safety PSO - P0186
Component of Parent Org(s):
  • Louisiana Hospital Association
Effective Date and Time of Initial Listing: November 8, 2016 12:01 AM ET
Mailing address: 9521 Brookline Ave, Baton Rouge, LA 70809
PSO Phone Number: 225-928-0026
Point of Contact: Floyd J. Roberts Jr., MD, FACP, FCCP
Point of Contact Phone: 225-928-0026, ext. 206
Point of Contact Email: froberts@lhaonline.org (link is external)
Two Bona Fide Contract Requirement: Next attestation period is 11/08/2020 through 11/07/2022
Disclosures & Finding: None
Subject to FDA-Regulated Reporting Entity Guidance: No